Answers are grounded in this paper and cite their sources.
Examines immune network changes after B cell-depletion therapy in NMOSD, suggesting effective treatment.
To determine whether B cell-depletion therapy (BCDT) with rituximab (RTX) reconfigures remission-phase immune networks in aquaporin-4 immunoglobulin G (AQP4-IgG)–positive neuromyelitis optica spectrum disorder (NMOSD), compared with conventional immunosuppression using azathioprine (AZA).
No takes yet. Share an insight, caveat, or question.
Lee et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: